The European Medicines Agency (EMA) has begun a rolling review of the AstraZeneca-Oxford coronavirus vaccine candidate, it said in a statement. The EMA says that the agency uses a rotating review of the agency's regulatory tools to speed up the determination of the promised medicine or vaccine during public health emergencies, "and this basically means that it has been done instead of evaluating all data after the vaccine." The decision to start a revolving review of the vaccine, based on preliminary results from non-clinical and preliminary clinical studies, suggests that the vaccine begins to produce antibodies and T cells (cells of the immune system, the body's natural defenses) that target viruses, "the EMA statement said. . "Rolling reviews will continue until there is sufficient evidence to support a formal marketing approval application."
😊😊😊😊😊